Study About Effect of Saxagliptin on Circulating Endothelial Progenitor Cells and Endothelial Function in Newly Diagnosed Type 2 Diabetic Patients | NCT02920801 | Trialant
CompletedInterventionalPhase 4Updated Oct 3, 2016
Study About Effect of Saxagliptin on Circulating Endothelial Progenitor Cells and Endothelial Function in Newly Diagnosed Type 2 Diabetic Patients
ClinicalTrials.gov ID
NCT02920801
Lead Sponsor
Shanghai Zhongshan HospitalOTHER
Overall Status
Completed
Study Type
Interventional
Phase
Phase 4
Enrollment
31Actual
Last Update Posted
Oct 3, 2016Estimated
Start Date
Dec 2014
Primary Completion Date
Jul 2015Actual
Completion Date
Jul 2015Actual
Brief Summary
In this study, the investigators aim to investigate whether saxagliptin modulate endothelial progenitor cells number and flow-mediated dilation in newly diagnosed, treatment-naive type 2 diabetic patients.
Type 2 Diabetes Mellitus
saxagliptin
Metformin
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
newly diagnosed type 2 diabetics (diagnosis were made according to the American Diabetes Association Guideline [19] ), treatment naive, age 30-75, hemoglobin A1c (HbA1c) ≥6.5%, fasting c-peptide >1.0ng/L
Exclusion Criteria:
pregnancy or lactation, smoker, acute disease or infection, chronic renal disease (estimated glomerular filtration rate <60 mL/min/1.73m2), live enzymes 3 times above the normal range, positive islet autoantibody, fasting c-peptide <1.0ng/L, severe hypertriglyceridemia (triglyceride >5.6mmol/L), cardiovascular events or surgery within 3 months, taking glucocorticoid, history of acute or chronic pancreatitis, pancreatic tumor, severe cardiac or pneumonic disease.